Ryan Flynn, PhD
GlycoRNA Specialist, Harvard University
Dr. Ryan Flynn is a leading researcher in the field of GlycoRNA, focusing on the intersection of RNA biology and glycoscience. His pioneering work explores the roles of glycosylated RNAs in cellular processes and disease mechanisms. Dr. Flynn has published extensively in top-tier journals and continues to advance our understanding of how these complex molecules influence health and development. He is currently an Assistant Professor at Harvard University, where he leads groundbreaking research projects aimed at uncovering novel therapeutic targets through GlycoRNA insights.
Noortje de Haan, PhD
Assistant Professor, Leiden University Medical Center
Dr. Noortje de Haan is an Assistant Professor at the Center for Proteomics and Metabolomics at Leiden University Medical Center. Her research focuses on the development and application of mass spectrometry-based methods for analyzing (antibody) glycosylation. She aims to identify tissue glycans involved in disease initiation and progression. Dr. de Haan received her PhD from Leiden University Medical Center in 2019, and her passion for glycoproteomics has been a driving force throughout her career. She is dedicated to advancing mass spectrometric methods and data analysis to address pressing clinical research challenges.
Ana Magalhães, PhD
Lecturer in Glycobiology, University of Porto
Ana Magalhães graduated in Biochemistry (2005) and holds a PhD in Biomedicine (2011) by University of Porto. She got trained in proteomics at the BRC-Centre of Excellence of the European Union (Hungary), in Proximity Ligation Assays at Uppsala University (Sweden), in cancer glycobiology at the Institute of Molecular Pathology and Immunology of University of Porto (Portugal) and in bacterial adhesion and pathogen adaptation at Umea University (Sweden).
Ana co-authored more than 50 scientific articles, including highly prestigious journals such as Cancer Cell, PNAS, Nature Cell Biology, Developmental Cell and J Biol Chem. Her publications have received more than 2400 citations (H-index 29). She has successfully complete the supervision of 4 PhD and 6 MSc students, as main or co-supervisor. All these dissertations articulate fundamental and clinical research.
At present, Ana is an Assistant Professor of Biochemistry at ICBAS- Scholl of Medicine and Biomedical Science and Investigator at i3S – University of Porto and her main research interests are focused on the mechanistic roles of proteoglycans in cancer-extracellular matrix dynamics and cell communication and signaling.
Yvette van Kooyk, PhD
Professor of Molecular Cell Biology and Immunology, Amsterdam UMC
Dr. Yvette van Kooyk is a leading expert in the field of immunology and glycobiology. Her research focuses on the role of glycan structures in immune recognition, particularly in the context of infectious diseases and cancer. Dr. van Kooyk has made significant contributions to the understanding of how glycan-mediated interactions influence immune responses and has pioneered work in designing glycan-based immunotherapies. She is currently a professor at Amsterdam UMC, where she leads research efforts aimed at developing novel therapeutic approaches targeting immune pathways.
Andres Salumets, PhD
Professor of Reproductive Medicine, Karolinska Institute
Dr. Andres Salumets is a prominent figure in reproductive medicine, with a focus on assisted reproductive technologies (ART) and embryology. His research investigates the factors that affect embryo quality and successful implantation, aiming to improve outcomes for patients undergoing fertility treatments. As a professor at the Karolinska Institute, Dr. Salumets leads a research team dedicated to advancing the science of reproduction and improving clinical practices in ART.
Matthew Wilson, PhD
Senior Postdoctoral Fellow in Glycobiology, KU Leuven
Dr. Matthew Wilson is a distinguished professor in the field of glycobiology, with a research focus on the role of glycans in cell signaling and disease. His work explores how glycosylation affects various biological processes, particularly in the context of neurodegenerative diseases and cancer. Dr. Wilson leads an innovative research group at KU Leuven, where his team is working on identifying glycan-based biomarkers and therapeutic targets to improve patient outcomes.
